Clinical Trial Update: Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating selinexor with high-dose melphalan before autologous stem cell transplantation in multiple myeloma; study completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Selinexor (selinexor)
• high-dose melphalan (melphalan)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-05-03